ALLR
NASDAQAllarity Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$1.55+0.48 (+44.50%)
2026-03-042026-06-05
News · 26 weeks39-95%
2025-12-142026-06-07
Mix2690d
- SEC Filings14(54%)
- Insider6(23%)
- Other5(19%)
- Dividends1(4%)
Latest news
25 items- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian cancer- Allarity has received a Notice of Allowance for new intellectual property covering its stenoparib-specific DRP® companion diagnostic- Strong financial position maintained with approximately $29.8 million in cash and restricted cash as of March 31, 2026 TARPON SPRINGS, Fla., MAY 15, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provide
- SECSEC Form 10-Q filed by Allarity Therapeutics Inc.10-Q - Allarity Therapeutics, Inc. (0001860657) (Filer)
- INSIDERCEO Jensen Thomas was granted 200,000 shares, increasing direct ownership by 50% to 596,734 units (SEC Form 4)4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
- INSIDERDirector Hoeiland Jesper was granted 25,000 shares (SEC Form 4)4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hoeiland Jesper3 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in StockholmTARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that CEO Thomas Jensen has been invited to participate as a speaker at Precision Medicine Forum Europe 2026, taking place May 11–12, 2026, in Stockholm, Sweden.Presentation Details: Event: Precision Medicine Forum Europe 2026Presentation Title: Dual Inhibition of PARP and WNT: A Novel Drug-Biomarker Combination in Clinical TrialsTrack: OncologyDate: Monday, May 11, 2026Time: 10:20–10:40 CEST Mr. Jensen will discus
- INSIDERDirector Mclaughlin Gerald W. was granted 45,000 shares, increasing direct ownership by 180% to 70,000 units (SEC Form 4)4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing CampaignPhase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting expected pivotal trial in advanced ovarian cancerSupports accelerating stenoparib toward FDA approval following FDA Fast Track designationAll manufacturing-related payments completed; no additional cash outlays for manufacturing are anticipated TARPON SPRINGS, Fla., MAY 5, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that its active pharmaceutical ingredient (API) manufacturing campaign f
- SECSEC Form DEFA14A filed by Allarity Therapeutics Inc.DEFA14A - Allarity Therapeutics, Inc. (0001860657) (Filer)
- SECSEC Form DEF 14A filed by Allarity Therapeutics Inc.DEF 14A - Allarity Therapeutics, Inc. (0001860657) (Filer)
- INSIDERAmendment: Officer Graff Jeremy R. was granted 133,333 shares, increasing direct ownership by 54% to 381,644 units (SEC Form 4)4/A - Allarity Therapeutics, Inc. (0001860657) (Issuer)
- INSIDERCFO Ervin Jeffrey S was granted 150,000 shares (SEC Form 4)4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark OfficePatent expected to be formally granted within three months, subject to standard administrative proceduresPatent would provide exclusivity at least into 2039 for stenoparib when used in concert with the stenoparib DRP test TARPON SPRINGS, Fla., April 27, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application covering the Company's DRP® companion diagnostic specific to stenoparib. Importan
- SECSEC Form 424B3 filed by Allarity Therapeutics Inc.424B3 - Allarity Therapeutics, Inc. (0001860657) (Filer)
- SECSEC Form EFFECT filed by Allarity Therapeutics Inc.EFFECT - Allarity Therapeutics, Inc. (0001860657) (Filer)
- SECAmendment: SEC Form S-3/A filed by Allarity Therapeutics Inc.S-3/A - Allarity Therapeutics, Inc. (0001860657) (Filer)
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib's Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian CancerNew AACR data highlight stenoparib's potential in colorectal cancer through WNT pathway modulationThe Stenoparib-DRP® companion diagnostic is associated with enhanced overall survival in Ovarian Cancer patientsPosters now available on Allarity's website TARPON SPRINGS, Fla., April 21, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today announced that it has published two scientific posters being presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17–22 in San
- SECSEC Form PRE 14A filed by Allarity Therapeutics Inc.PRE 14A - Allarity Therapeutics, Inc. (0001860657) (Filer)
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Therapeutics Reports Full Year 2025 Financial Results and Corporate ProgressStrengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for stenoparib, enabling accelerated development in advanced ovarian cancerDurable clinical benefit observed in ongoing stenoparib ovarian cancer study, including patients treated for nearly 30 months, with new Phase 2 protocol implementedExpansion of stenoparib development beyond ovarian cancer with the launch of a VA-funded Phase 2 combination study in recurrent small cell lung cancer TARPON SPRINGS, Fla., March 31, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2
ALLR FAQ
6 questionsWhat does Allarity Therapeutics Inc. do?
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials...Where does ALLR stock trade?
Allarity Therapeutics Inc. (ALLR) is listed on NASDAQ.What sector and industry is ALLR in?
Allarity Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ALLR?
Allarity Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from Ascendiant Capital Markets: Buy with a $900.00 price target on 2025-07-28. Recent price targets cluster around $900.00.What companies are similar to ALLR?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ALLR side-by-side with any of them on Quantisnow.How can I track ALLR on Quantisnow?
Quantisnow aggregates Allarity Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALLR to receive live email and push alerts on every new disclosure.